Status:
COMPLETED
Dose Escalation Trial of Dalotuzumab (MK-0646) in Advanced Solid Tumors and Multiple Myeloma (MK-0646-001)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Solid Tumor
Multiple Myeloma
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This study will look for the highest tolerated dose of dalotuzumab (MK-0646) given as weekly, every other week. or a every three week infusion. The hypothesis of this study is that administration of ...
Detailed Description
Trial Duration of Treatment: Participants can be treated for up to two years if their disease has not progressed and they are not having unmanageable side effects.
Eligibility Criteria
Inclusion
- Participant has metastatic or locally advanced solid tumor or multiple myeloma
- Tumor specimen has IGF-1R expression
- Participant agrees to use birth control throughout study
Exclusion
- Participant must not be recovering from antineoplastic therapy in the last 4 weeks
- Participant has participated in a clinical trial in the last 4 weeks
- Participant has a history of heart problems such as congestive heart failure, angina, heart attack or stroke in the last 3 months
- Participant is taking growth hormone or growth hormone inhibitors
- If female, participant is pregnant or breastfeeding
- Participant is human immunodeficiency virus (HIV) positive
- Participant has a history of hepatitis B or C
Key Trial Info
Start Date :
January 12 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2009
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT00701103
Start Date
January 12 2006
End Date
December 1 2009
Last Update
August 8 2018
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.